Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QBECO SSI in Moderate to Severe Ulcerative Colitis
NCT02426372Phase 2Completed
- Sponsor
- Qu Biologics
- Start
- Jul 2015
- Primary completion
- Dec 2016
- Modality
- Split/Subunit Vaccines, Live Attenuated Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of QBECO SSI in ulcerative colitis (UC), sponsored by Qu Biologics. Started Jul 2015; status: completed.
02
Drugs
QBECO SSI
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02426372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02426372.